Germany has found a convenient way to cut healthcare costs: send the bill for medical innovation to the United States.
Under a new policy, Germany will tighten its already aggressive controls on what drugmakers can charge for innovative medicines. The result is predictable: Germany will contribute even less toward the cost of developing new treatments while American patients shoulder more of the burden.